Treatment with RXRs agonists, such as bexarotene, inhibits tumor angiogenesis, suppresses the proliferation and migration of lung tumor cells, and promotes tumor cell death through the PPARγ, PTEN, and mTOR pathways [96]. Here, PPARG is linked to neoplasm.